Study Plan and Starting Data for Using GLP-1 Drugs After Weight-Loss Surgery

The GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Trial will investigate tirzepatide in patients with persistent obesity after Roux-en-Y gastric bypass.

• No prior studies have examined the combined effectiveness of GLP1RAs in the context of persistent obesity post-bariatric surgery.
• The trial will compare tirzepatide with standard care in patients who have a body mass index (BMI) of 30 kg/m² or higher.
• The focus is on individuals who continue to struggle with obesity despite having undergone Roux-en-Y gastric bypass.

Simplified